DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. Their lead candidate, DM199, is a recombinant form of the KLK1 protein, aimed at restoring healthy levels of this protein to treat vascular diseases. The company focuses on developing therapies that enhance blood flow and reduce inflammation, with ongoing clinical trials for stroke and pregnancy complications.
Industries
Nr. of Employees
small (1-50)
DiaMedica Therapeutics Inc
Minneapolis, Minnesota, United States, North America
Patents
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US-9616015-B2
View Details
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US-9616015-B2
View DetailsProducts
Investigational recombinant human tissue kallikrein-1 therapeutic (recombinant KLK1)
An investigational recombinant protein intended to restore physiological levels of the tissue kallikrein-1 protein to modulate blood flow, inflammation and oxidative stress; being evaluated as an injectable therapeutic for vascular-related indications.
Investigational recombinant human tissue kallikrein-1 therapeutic (recombinant KLK1)
An investigational recombinant protein intended to restore physiological levels of the tissue kallikrein-1 protein to modulate blood flow, inflammation and oxidative stress; being evaluated as an injectable therapeutic for vascular-related indications.
Services
Sponsorship and operational conduct of interventional clinical trials (Phase 1–3) including site coordination, investigator collaboration and trial oversight.
End-to-end planning and management of investigational product packaging, labeling, distribution, temperature-controlled shipment handling, depot management, returns and destruction.
Partnerships with academic hospitals and principal investigators to run investigator-led and sponsor-partnered clinical studies.
Sponsorship and operational conduct of interventional clinical trials (Phase 1–3) including site coordination, investigator collaboration and trial oversight.
End-to-end planning and management of investigational product packaging, labeling, distribution, temperature-controlled shipment handling, depot management, returns and destruction.
Partnerships with academic hospitals and principal investigators to run investigator-led and sponsor-partnered clinical studies.
Expertise Areas
- Clinical trial management
- Biologics discovery and development
- Biomanufacturing and CMC
- Clinical supplies and logistics
Key Technologies
- Recombinant protein therapeutics
- Mammalian cell line expression systems
- Intravenous and subcutaneous formulation development
- Adaptive randomized clinical trial methods
News & Updates
DiaMedica Therapeutics will present at the Jefferies Global Healthcare Conference 2025.
A webinar discussing DM199 (rinvecalinase alfa) for preeclampsia.
A poster presentation at ESOC 2025.
DiaMedica Therapeutics will present at the Jefferies Global Healthcare Conference 2025.
A webinar discussing DM199 (rinvecalinase alfa) for preeclampsia.
A poster presentation at ESOC 2025.